Janney Montgomery Scott LLC increased its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 34.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 120,550 shares of the exchange traded fund’s stock after purchasing an additional 30,819 shares during the quarter. Janney Montgomery Scott LLC owned 0.19% of SPDR S&P Biotech ETF worth $15,398,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Avoro Capital Advisors LLC purchased a new stake in shares of SPDR S&P Biotech ETF during the 4th quarter worth $256,053,000. Wells Fargo & Company MN increased its holdings in shares of SPDR S&P Biotech ETF by 75.7% in the 4th quarter. Wells Fargo & Company MN now owns 3,566,265 shares of the exchange traded fund’s stock valued at $434,835,000 after purchasing an additional 1,536,122 shares in the last quarter. OMERS ADMINISTRATION Corp increased its holdings in shares of SPDR S&P Biotech ETF by 42,425.2% in the 4th quarter. OMERS ADMINISTRATION Corp now owns 1,190,707 shares of the exchange traded fund’s stock valued at $145,147,000 after purchasing an additional 1,187,907 shares in the last quarter. Morgan Stanley lifted its stake in shares of SPDR S&P Biotech ETF by 8.3% in the fourth quarter. Morgan Stanley now owns 11,491,683 shares of the exchange traded fund’s stock valued at $1,401,181,000 after purchasing an additional 882,718 shares during the period. Finally, Assetmark Inc. lifted its stake in shares of SPDR S&P Biotech ETF by 1,042,265.6% in the fourth quarter. Assetmark Inc. now owns 635,843 shares of the exchange traded fund’s stock valued at $77,528,000 after purchasing an additional 635,782 shares during the period.
SPDR S&P Biotech ETF Price Performance
Shares of NYSEARCA:XBI opened at $158.25 on Wednesday. The business’s 50 day simple moving average is $136.09 and its 200-day simple moving average is $129.25. The firm has a market capitalization of $10.10 billion, a price-to-earnings ratio of 11.47 and a beta of 0.85. SPDR S&P Biotech ETF has a 12 month low of $82.04 and a 12 month high of $160.01.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Read More
- Five stocks we like better than SPDR S&P Biotech ETF
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
